High-risk AML

This short collection of expert insights on high-risk acute myeloid leukaemia (AML) has been selected from Jazz Pharmaceuticals sponsored promotional EBMT and EHA 2020 symposia featuring data presented by Prof Thomas Cluzeau, Prof Nigel Russell and Dr Donal McLornan. High-risk AML is defined as therapy related AML (t-AML) or AML with myelodysplasia- related changes (AML-MRC).